Information Provided By: 
Fly News Breaks for December 31, 2015
AXDX
Dec 31, 2015 | 05:59 EDT
Piper Jaffray analyst William Quirk reiterates an Overweight rating on Accelerate Diagnostics with a $25 price target. Management is in the process of building out U.S. and European commercial teams with U.S. clinical trials now enrolling, Quirk tells investors in a research note. He believes Accelerate is poised to disrupt the microbiology market.
News For AXDX From the Last 2 Days
There are no results for your query AXDX
